Sanofi scraps most atopic dermatitis trials after amlitelimab fails to outperform standard care

Sanofi announced it is halting all but one ongoing trial for amlitelimab, an OX40‑ligand antibody acquired through its $1.4 billion purchase of Kymab.

The decision follows the Phase 3 COAST‑1 study in atopic dermatitis, where the drug reduced skin lesions but did not achieve a meaningful improvement compared with the current standard of care.

Although a long‑term extension showed sustained response, Sanofi concluded the overall efficacy and safety data do not justify further development in atopic dermatitis, and the asset will be discontinued for that indication.

The setback leaves Sanofi seeking alternatives to replace Dupixent as its flagship immunology product approaches a patent cliff.